Recent Posts
- FDA Issued Guidance to Help Identify Suspect and Illegitimate Product in the U.S. Pharmaceutical Distribution Supply Chain
- FDA Released Draft Guidance on the Use of Electronic Systems, Records, and Signatures in Clinical Investigations
- FDA Released Recommendations that Assist in the Development of Monoclonal Antibodies (mAbs) and other Therapeutic Proteins
- New Guidance Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products from FDA
- FDA Published New Draft Guidance for M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms